Clinical-Grade Wearable for Pharma and Biotech Market Global Report 2026

The clinical-grade wearable for pharma and biotech market size has grown exponentially in recent years. It will grow from $2.83 billion in 2025 to $3.43 billion in 2026 at a compound annual growth rate (CAGR) of 21.3%. The growth in the historic period can be attributed to increasing adoption of wearable medical devices in clinical trials, growing demand for real-world patient data, expansion of decentralized clinical trials, improvements in biosensor technologies, growth in digital healthcare infrastructure.

The clinical-grade wearable for pharma and biotech market size is expected to see exponential growth in the next few years. It will grow to $7.48 billion in 2030 at a compound annual growth rate (CAGR) of 21.5%. The growth in the forecast period can be attributed to the integration of artificial intelligence in clinical data analysis, the expansion of personalized drug development methodologies, the increased use of remote patient monitoring in clinical trials, the growing regulatory acceptance of real-world evidence, and the development of advanced next-generation wearable sensors for clinical applications. Major trends in the forecast period include AI-driven clinical wearable data analytics platforms for pharmaceutical trials, IoT-enabled continuous biosignal monitoring systems, cloud-based real-world evidence generation platforms, precision medicine-integrated wearable biomarker tracking solutions, and Industry 4.0-enabled smart medical device manufacturing systems.

The rising demand for remote patient monitoring is expected to drive the growth of the clinical-grade wearable for pharma and biotech market going forward. Remote patient monitoring (RPM) refers to the use of digital technologies and electronic devices to collect patients’ health data outside traditional healthcare settings, enabling healthcare providers to monitor, track, and manage their health remotely. The demand for remote patient monitoring is increasing as more individuals are living with chronic conditions such as heart disease, diabetes, and hypertension, which require continuous monitoring and timely medical interventions for effective management. Clinical-grade wearables for pharma and biotech enable continuous, real-time physiological data collection that enhances remote patient monitoring by allowing clinicians to track patient health trends, detect early deterioration, and adjust treatments without requiring in-person visits. For instance, in August 2023, according to Vivalink, a US-based healthcare technology company, a recent survey revealed that 84% of respondents currently using RPM plan to increase their usage in 2024, 45% of providers utilize RPM for acute monitoring such as hospital-at-home programs, and 77% predict that RPM-based care will surpass traditional in-patient hospital care within the next five years. Therefore, the rising demand for remote patient monitoring is driving the growth of the clinical-grade wearable for pharma and biotech market.

Leading companies operating in the clinical-grade wearable for pharma and biotech market are focusing on the development of advanced solutions, such as wearable injector technologies, to enhance biologic drug delivery, support self-administration, and improve patient convenience. Wearable injector technology refers to a drug delivery system designed to administer large-volume and high-viscosity biologic therapies via subcutaneous delivery using a body-worn device, enabling patients to receive treatment outside traditional hospital settings. For example, in July 2025, Becton, Dickinson and Company, a US-based medical technology company, announced the first pharma-sponsored clinical trial utilizing its BD Libertas wearable injector technology for biologic drug delivery. The BD Libertas wearable injector is a prefilled, patient-ready drug delivery system designed for subcutaneous administration of complex biologics. The platform enables delivery of high-viscosity biologics up to 50 centipoise and is available in 2-5 mL and 5-10 mL configurations, offering flexibility across multiple therapeutic applications. The technology selection was based on successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a clinical study in which 100% of participants indicated they would likely use the device if prescribed.

In March 2026, Thermo Fisher Scientific Inc., a US-based life sciences and biotechnology company, acquired Clario Holdings Inc. for $8.875 billion. Through this acquisition, Thermo Fisher aims to enhance its clinical research and digital capabilities by integrating advanced endpoint data solutions, thereby enabling faster and more informed drug development processes. Clario Holdings Inc. is a US-based company that provides clinical-grade wearable technologies and connected devices for pharmaceutical, biotechnology, and medical device partners.

Major companies operating in the clinical-grade wearable for pharma and biotech market are Abbott Laboratories, Medtronic plc, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Boston Scientific Corporation, DexCom Inc., iRhythm Technologies Inc., Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed AG, Oura Health Oy, Whoop Inc., Biofourmis Inc., BioSerenity, AliveCor Inc., VitalConnect Inc., Empatica Inc., Sibel Health Inc., VivaLNK Inc., Blue Spark Technologies Inc., BioBeat Technologies Ltd., Carré Technologies Inc.

North America was the dominated region in the clinical-grade wearable for pharma and biotech market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in clinical-grade wearable for pharma and biotech report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clinical-grade wearable for pharma and biotech market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The clinical-grade wearable for pharma and biotech market consists of sales of ambulatory blood pressure monitors, inertial measurement unit motion trackers, smart medication adherence wearables, and neuromodulation wearables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The clinical-grade wearable for pharma and biotech market research report is one of a series of new reports that provides clinical-grade wearable for pharma and biotech market statistics, including clinical-grade wearable for pharma and biotech industry global market size, regional shares, competitors with a clinical-grade wearable for pharma and biotech market share, detailed clinical-grade wearable for pharma and biotech market segments, market trends and opportunities, and any further data you may need to thrive in the clinical-grade wearable for pharma and biotech industry. This clinical-grade wearable for pharma and biotech market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.